furosemide has been researched along with enalaprilat anhydrous in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ax, F; Bonham, NM; Hallberg, A; Karlén, A; Lennernäs, H; Winiwarter, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andersson, G; Held, P; Sigurdsson, A; Swedberg, K | 1 |
| Anderson, GH; Hellwig, B; Kopecky, RT; McAfee, JG; Patchin, D; Roskopf, M; Thomas, FD | 1 |
| Ayers, C; Davidson, R; DiPette, D; Fisher, M; Guthrie, G; Rucinska, E; Rutledge, J; Schwartz, S | 1 |
| Denton, DA; Di Nicolantonio, R; McKinley, MJ; Weisinger, RS | 1 |
| de Jong, PE; de Zeeuw, D; Donker, AJ; Navis, GJ; van der Hem, GK | 1 |
| Connelly, JF; Zigmont, EA | 1 |
| Berdeaux, A; Giudicelli, JF; Richard, V | 1 |
| Berdeaux, A; Ghaleh, B; Giudicelli, JF; Richard, V | 1 |
| Ferraro, T; May, C; Tarjan, E; Weisinger, RS | 1 |
| Blossom, G; Czako, PF; Glover, JL; Juleff, R; Long, GW; Misra, DC | 1 |
| Bak, M; Christensen, S; Petersen, JS; Poulsen, LB; Shalmi, M | 1 |
| Kutina, AV; Natochin, IuV; Shakhmatova, EI | 1 |
1 review(s) available for furosemide and enalaprilat anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for furosemide and enalaprilat anhydrous
| Article | Year |
|---|---|
Enalaprilat in acute myocardial infarction: tolerability and effects on the renin-angiotensin system.
Topics: Aged; Blood Pressure; Enalaprilat; Female; Furosemide; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Metoprolol; Middle Aged; Myocardial Infarction; Nitroglycerin; Renin-Angiotensin System; Thrombolytic Therapy | 1991 |
Effect of intravenous enalaprilat in moderate and severe systemic hypertension.
Topics: Antihypertensive Agents; Double-Blind Method; Enalapril; Enalaprilat; Female; Furosemide; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Random Allocation | 1988 |
20 other study(ies) available for furosemide and enalaprilat anhydrous
| Article | Year |
|---|---|
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
Topics: Humans; Intestinal Absorption; Jejunum; Models, Biological; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship | 1998 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Enalaprilat-enhanced renography in a rat model of renovascular hypertension.
Topics: Animals; Enalaprilat; Furosemide; Hypertension, Renovascular; Kidney; Male; Organotechnetium Compounds; Pentetic Acid; Radioisotope Renography; Rats; Rats, Inbred Strains; Succimer; Technetium Tc 99m Dimercaptosuccinic Acid; Technetium Tc 99m Pentetate; Time Factors | 1990 |
The effect of captopril or enalaprilic acid on the Na appetite of Na-deplete rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Appetite; Captopril; Drinking; Enalaprilat; Food Deprivation; Furosemide; Male; Rats; Rats, Inbred Strains; Sodium; Sodium, Dietary; Water Deprivation | 1988 |
Blood pressure response to enalaprilic acid in essential hypertension: dose-response and effect of pre-treatment with furosemide.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Dose-Response Relationship, Drug; Enalapril; Enalaprilat; Female; Furosemide; Heart Rate; Humans; Hypertension; Male; Middle Aged; Renin | 1985 |
Intravenous antihypertensive agents for patients unable to take oral medications.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Enalaprilat; Furosemide; Humans; Hydralazine; Hypertension; Injections, Intravenous; Labetalol; Methyldopa; Nitroglycerin; Nitroprusside; Vasodilator Agents | 1995 |
Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Coronary Circulation; Dogs; Enalaprilat; Female; Furosemide; Hemodynamics; Imidazoles; Losartan; Male; Renin-Angiotensin System; Tetrazoles | 1993 |
Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dogs; Enalaprilat; Female; Furosemide; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Renin-Angiotensin System; Tetrazoles | 1993 |
Converting enzyme inhibition in rabbits: effects on sodium and water intake/excretion and blood pressure.
Topics: Animals; Blood Pressure; Enalaprilat; Female; Furosemide; Male; Natriuresis; Rabbits; Sodium Chloride; Thirst; Water-Electrolyte Balance | 1993 |
Protective effects of enalaprilat against postischemic renal failure.
Topics: Analysis of Variance; Animals; Blood Urea Nitrogen; Creatinine; Dogs; Enalaprilat; Furosemide; Ischemia; Kidney; Mannitol; Renal Insufficiency; Time Factors | 1993 |
Effects of angiotensin-converting enzyme inhibition on renal adaptations to acute furosemide administration in conscious rats.
Topics: Absorption; Adaptation, Physiological; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Fluids; Consciousness; Drug Interactions; Enalaprilat; Female; Furosemide; Heart Rate; Kidney; Kidney Tubules; Peptidyl-Dipeptidase A; Potassium; Rats; Rats, Wistar; Renal Circulation; Sodium; Solutions; Time Factors; Water | 1993 |
[Influence of the angiotensin converting enzyme inhibition on the functional proteinuria in rats].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Diuresis; Diuretics; Dose-Response Relationship, Drug; Enalaprilat; Female; Furosemide; Glomerular Filtration Rate; Kidney; Peptidyl-Dipeptidase A; Potassium; Proteinuria; Rats; Rats, Wistar; Vasotocin; Water | 2009 |